Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart Twice Daily and Biphasic Insulin Aspart Twice Daily in Subjects With Type 2 Diabetes Mellitus Before, During and After Ramadan
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 263 participants.
Also called NCT02648217
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 263 participants
- Sponsor
- Registry
-
NCT02648217
-
- Other papers using this trial's data
- Original paper: Efficacy and safety analysis of insulin degludec/insulin aspart compared with biphasic insulin aspart 30: A phase 3, multicentre, international, open-label, randomised, treat-to-target trial in patients with type 2 diabetes fasting during Ramadan
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Algeria, India, Lebanon, Malaysia, South Africa, United Arab Emirates
- Registry status
- Completed
Technical summary
Registry record NCT02648217. Randomized; no masking; primary purpose treatment. Start 2016-01-04 (actual); primary completion 2016-09-04 (actual). Results posted on 2018-09-11.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart Twice Daily and Biphasic Insulin Aspart Twice Daily in Subjects With Type 2 Diabetes Mellitus Before, During and After Ramadan
- Condition
- Diabetes
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- insulin degludec/insulin aspart
- Intervention (Drug)
- biphasic insulin aspart
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct02648217- Content hash
503ce602728815c1cf0620490db49adc5fce269dbaadd1fe85acdb97d89664d3